This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

4 Drug Stocks Poised to Stage Comeback

Cephalon (CEPH)

Founded in 1987 as a biotech startup, Cephalon has emerged as one of the world's top 10 biopharmaceutical companies, with an impressive roster of first-in-class products, and total revenue of $2.19 billion in 2009. The company's portfolio includes treatments for central nervous system disorders, pain and cancer. Cephalon boasts eight proprietary products in the U.S., along with more than 100 products internationally.

The company's stock performance over the past 12 months, however, has been nothing to brag about, with its shares falling over 6%. Nevertheless, Auer expects that to change in the coming year.

"Cephalon's stock has been slightly down in the past year, yet the 2010 estimates by a consensus of 26 analysts has risen to $7.80 per share from $6.03 in 2009. Meanwhile, sales are expected to jump 26% to $2.77 billion and with a market cap of about $4.5 billion, this company is very digestible for one of the bigger players," says Auer.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player
2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
JNJ $102.52 0.54%
MNTA $10.43 -3.70%
MRK $49.93 1.60%
PFE $29.60 1.70%
XLV $65.10 1.70%


Chart of I:DJI
DOW 16,125.97 +111.59 0.70%
S&P 500 1,876.80 +24.59 1.33%
NASDAQ 4,356.3710 +87.6080 2.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs